



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

Press Release

ESSEX BIO-TECHNOLOGY LIMITED SUCCESSFULLY TRANSFER THE LISTING FROM THE GEM BOARD TO THE MAIN BOARD

(Stock Code on Main Board: 1061)

(Stock Code on GEM: 8151)

Hong Kong, 23 June 2011 ----- ESSEX BIO-TECHNOLOGY LIMITED (“Essex” or the “Company”) successfully transfer the Listing from the GEM Board to the Main Board today.

Essex made an application to the Stock Exchange for the transfer of listing from GEM to the Main Board on 20 April 2011 and was approved on 22 June 2011. The last day of dealings in the Shares on GEM was 22 June 2011 and the dealings in the Shares on the Main Board commenced today.

The Board believes that the transfer of listing will improve the liquidity of the shares and enhance the profile of the Company. The Board considers that the transfer of listing will be beneficial to the future growth and business development of the Group as well as its financing flexibility.

Chairman Patrick Ngiam said, “The migration to the Main Board marks a momentous milestone for the Company and is a testament of the Group’s achievements since it’s listing on GEM on 27 June 2001. It is a further endorsement to all members of the Group for their relentless efforts and contributions rendered over the past 10 years.”

“On behalf of the Company, I like to thank all my dedicated colleagues, business associates and those who have rendered support to the Company all these years.”

About Essex Bio-Technology Limited:

Essex Bio-Technology Limited (“Essex”) was listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited on 27 June 2001 and under stock code (8151) during the period from 27 June 2001 to 22 June 2011. The Listing was transferred from GEM Board to the Main Board on 23 June 2011 and under stock code (1061).

Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds and the research and development of biopharmaceutical products for the treatment of duodenal ulcers and nervous system damages and diseases, as well as other ophthalmic pharmaceutical projects.

For more information, please contact:

Essex Bio-Technology Limited

Email : essex@essexbio.com

Tel : (852) 2587-7838

Fax : (852) 2587-7363